Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Bridgebio Pharma IncBBIO-11.0023.17-4.90-12.6947.91%-13.15%35.31$25.39$35.7331,001$27.07

Detail of Bridgebio Pharma Inc

 
CEO
Dr. Neil Kumar Ph.D.
Employees
576
Industry
Biotechnology
Sector
Healthcare
Market cap
$5B

Company details

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Revenue
CoG
Gross profit
OE
R&D
G&A
OI
OIE
PI
NI
Revenue (Rev)
$219.12M
Cost of goods (CoG)
-$1.79M
Gross profit (GP)
$213.24M
Operating expense (OE)
-$720.32M
Research and development (R&D)
-$511.63M
General and administrative (G&A)
-$208.69M
Operating income (OI)
-$502.99M
Other income expense (OIE)
-$109.81M
Pretax income (PI)
-$461.52M
Net income (NI)
-$461.52M
Bridgebio Pharma Inc
BBIO • XNGS • US
$27.07
-4.50 (-14.24%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.46
Margin profit
-201.53%
52 week low
$21.789101
52 week high
$43.889999
50-day simple moving average
$25.30
200-day simple moving average
$25.39
Percent held by insiders
5.40%
Percent held by institutions
94.45%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
BBIO -16.38%
eps change
BBIO 0.00%